求医问诊网用户请注册后联系站长QQ 5825256,验证语言-医院。允许通过后投稿。
您好,请 【登陆】【注册】
求医问诊网共有:6个海外医院 , 个病历正在排队审核 , 共有:97618篇出国看病资讯。
今日热门:
您现在的位置:主页 > 出国看病 > 印度求医 >

一个转化医学的世纪典范”的前世今生说开去

作者:admin 发布时间:2019.09.08 浏览:

由 “格列卫 — 一个转化医学的世纪典范”的前世今生说开去

 

刘乔飞

北京协和医院基本外科

前言

1. 费城染色体的庐山真面目

 

2. 从STI-571到Sunitinib 

完成了其生物物理学作用机制的阐释。   

分别于 ,辉瑞制药合作, 出国看病 ,完成了多种酪氨酸激酶的抑制剂 

 

 

总结

参考文献

1.    Nowell P C, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science, 1960, 132:1488–1501.

2.    Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 1973, 243:290–293

3.    de Klein A, van Kessel AG, Grosveld G et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature, 1982, 300: 765–767.

4.    Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 . Cell, 1984, 36(1):93-99.

5.    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nature Med, 1996, 2: 561-566.

6.    Zimmermann J, Buchdunger E, Mett H, et al. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioog. Med Chem Lett, 1997, 7:187-192.

7.    Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis, 1997, 23:380-394.

8.    Buchdunger E, Zimmermann J, Mett H, et al. Selective inhibition of the platelet-derivedgrowth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA, 1995, 92:2558–2562.

9.    Buchdunger E, Zimmermann J, Mett H. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res, 1996, 56:100–104.

10.  Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 1997, 90:3691–3698.

11.  Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. N Engl J Med, 2001, 344(14):1031-1037.

12.  Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science, 2000, 289(5486):1938-1942.

13.  Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic. Cancer Cell, 2002, 2(2):117-125.

14.  Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 2002, 99(6):1928-1937.

15.  Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006, 355(23):2408-2417.

16.  Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001, 293:876-880.

17.  Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2002, 2:117-125.

18.  Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 2004, 305: 399-401.

19.  Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med, 2006, 354: 2531-2541.

20.  Heinrich MC, Griffith DJ, Druker BJ, et al.Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood, 2000, 96(3):925-932.

21.  Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther, 2000, 295(1):139-145.

22.  Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med, 2001, 344(14):1052-1056.

23.  Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7):472-480.

24.  Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003, 299(5607):708-710.

25.  Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol , 2003, 21(23):4342-4349.

26.  Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, 368(9544):1329-38.

27.  Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, 2009, 373(9669):1097-1104.

0
赞一个
上一篇:郑州大学.学校概况 下一篇:没有了

评论

游客,你好!评论请填写验证码:点击我更换图片
最新评论